Vaccine development lessons between HIV and COVID-19.
作者信息
Vasan Sandhya, Pitisuttithum Punnee
机构信息
US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA; Henry M Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
Vaccine Trial Centre, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand.
出版信息
Lancet Infect Dis. 2021 Jun;21(6):759-761. doi: 10.1016/S1473-3099(21)00274-7.
Abstract
摘要
相似文献
1
Vaccine development lessons between HIV and COVID-19.艾滋病病毒与新冠病毒疫苗研发的经验教训
Lancet Infect Dis. 2021 Jun;21(6):759-761. doi: 10.1016/S1473-3099(21)00274-7.
2
HIV and SARS-CoV-2: Tracing a Path of Vaccine Research and Development.HIV 和 SARS-CoV-2：疫苗研发的溯源之路。
Curr HIV/AIDS Rep. 2022 Feb;19(1):86-93. doi: 10.1007/s11904-021-00597-4. Epub 2022 Jan 28.
3
HIV and SARS-CoV-2 Pathogenesis and Vaccine Development.HIV与新型冠状病毒肺炎的发病机制及疫苗研发
Viruses. 2022 Nov 22;14(12):2598. doi: 10.3390/v14122598.
4
Mixed outcomes following a third SARS-CoV-2 vaccine dose in previously unresponsive people with HIV.先前对新冠病毒无反应的HIV感染者接种第三剂严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗后的混合结果
J Clin Virol. 2023 Jan;158:105347. doi: 10.1016/j.jcv.2022.105347. Epub 2022 Nov 29.
5
Do not repeat mistakes from HIV in COVID-19 response.在应对新冠疫情时，不要重蹈艾滋病应对工作中的覆辙。
Lancet HIV. 2021 Feb;8(2):e59. doi: 10.1016/S2352-3018(21)00001-1. Epub 2021 Jan 22.
6
New vector and vaccine platforms: mRNA, DNA, viral vectors.新型载体和疫苗平台：mRNA、DNA、病毒载体。
Curr Opin HIV AIDS. 2022 Nov 1;17(6):338-344. doi: 10.1097/COH.0000000000000763.
7
Fast Development of High-Quality Vaccines in a Pandemic.大流行期间高质量疫苗的快速研发
Chest. 2021 Jul;160(1):e1-e3. doi: 10.1016/j.chest.2021.03.063. Epub 2021 Apr 20.
8
SARS-CoV-2 (COVID-19) Vaccine Development and Production: An Ethical Way Forward.SARS-CoV-2（COVID-19）疫苗的开发和生产：一条合乎道德的前进道路。
Camb Q Healthc Ethics. 2021 Jan;30(1):59-68. doi: 10.1017/S096318012000047X. Epub 2020 Jun 5.
9
[SARS-CoV-2 vaccination in people living with HIV].[HIV感染者中的新型冠状病毒2型疫苗接种]
MMW Fortschr Med. 2022 Jun;164(Suppl 2):34-39. doi: 10.1007/s15006-022-1021-x.
10
Anti-SARS-COV-2 specific immunity in HIV immunological non-responders after mRNA-based COVID-19 vaccination.mRNA 疫苗接种后 HIV 免疫无应答者的抗 SARS-CoV-2 特异性免疫。
Front Immunol. 2022 Aug 26;13:994173. doi: 10.3389/fimmu.2022.994173. eCollection 2022.
引用本文的文献
1
Evaluating enrollment and representation in COVID-19 and HIV vaccine clinical trials.评估 COVID-19 和 HIV 疫苗临床试验中的入组和代表性。
Front Public Health. 2024 Jul 26;12:1411970. doi: 10.3389/fpubh.2024.1411970. eCollection 2024.
2
The Interrelationship between HIV Infection and COVID-19: A Review of the Literature.HIV感染与COVID-19之间的相互关系：文献综述
Curr HIV Res. 2024;22(1):6-15. doi: 10.2174/011570162X282739231222062830.
3
Liquid-liquid phase separation of nucleocapsid proteins during SARS-CoV-2 and HIV-1 replication.SARS-CoV-2 和 HIV-1 复制过程中核衣壳蛋白的液-液相分离。
Cell Rep. 2023 Jan 31;42(1):111968. doi: 10.1016/j.celrep.2022.111968. Epub 2022 Dec 26.
本文引用的文献
1
Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates.脂质纳米颗粒包裹的核苷修饰mRNA疫苗在非人灵长类动物中引发的多功能HIV-1抗体与蛋白质相当。
NPJ Vaccines. 2021 Apr 9;6(1):50. doi: 10.1038/s41541-021-00307-6.
2
Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19.COVID-19 用 Ad26.COV2.S 疫苗的免疫原性。
JAMA. 2021 Apr 20;325(15):1535-1544. doi: 10.1001/jama.2021.3645.
3
Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial.抗中东呼吸综合征冠状病毒 DNA 疫苗的安全性和免疫原性：一项 1 期、开放性、单臂、剂量递增试验。
Lancet Infect Dis. 2019 Sep;19(9):1013-1022. doi: 10.1016/S1473-3099(19)30266-X. Epub 2019 Jul 24.
4
Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19).在一项多中心、随机、双盲、安慰剂对照的 1/2a 期临床试验（APPROACH）和恒河猴（NHP 13-19）中评估马赛克 HIV-1 疫苗。
Lancet. 2018 Jul 21;392(10143):232-243. doi: 10.1016/S0140-6736(18)31364-3. Epub 2018 Jul 6.
5
HIV Vaccine Efficacy Trials: RV144 and Beyond.HIV 疫苗功效试验：RV144 及其他。
Adv Exp Med Biol. 2018;1075:3-30. doi: 10.1007/978-981-13-0484-2_1.
6
Improving influenza vaccine virus selection: report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14-16 June 2010.改进流感疫苗病毒的选择：2010年6月14日至16日在瑞士日内瓦世界卫生组织总部举行的世卫组织非正式磋商会报告
Influenza Other Respir Viruses. 2013 Sep;7 Suppl 2(Suppl 2):52-53. doi: 10.1111/irv.12081.
7
Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus.设计并鉴定展示呼吸道合胞病毒 motavizumab 表位的抗原表位支架免疫原。
J Mol Biol. 2011 Jun 24;409(5):853-66. doi: 10.1016/j.jmb.2011.04.044. Epub 2011 Apr 27.
8
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.在泰国使用ALVAC和AIDSVAX疫苗预防HIV-1感染。
N Engl J Med. 2009 Dec 3;361(23):2209-20. doi: 10.1056/NEJMoa0908492. Epub 2009 Oct 20.
Zotero 插件